Ablynx Release: Nanobody for Alzheimer’s Disease From the Alliance With Boehringer Ingelheim Corporation Moves Closer Towards Phase I Clinical Trials

GHENT, BELGIUM--(Marketwire - April 25, 2012) - Ablynx [Euronext Brussels: ABLX] todayannouncedthat Boehringer Ingelheim has submitted a Clinical Trials Application(CTA) tothe European regula…
Read the full story: BioSpace.com Featured News